SCOR SE (SCRYY)

Verve Therapeutics Revenue

SCOR SE had revenue of 3.11B EUR in the quarter ending June 30, 2025, a decrease of -34.10%. This brings the company's revenue in the last twelve months to 16.15B, down -2.25% year-over-year. In the year 2024, SCOR SE had annual revenue of 16.46B with 1.34% growth.

• Revenue (ttm): 16.15B EUR
• Revenue Growth: -2.25%
• P/S Ratio: 0.30
• Revenue / Employee: 4.46M EUR
• Employees: 3,621
• Market Cap: 5.77B USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	16.46B	218.00M	1.34%
Dec 31, 2023	16.24B	258.00M	1.61%
Dec 31, 2022	15.98B	-1.69B	-9.57%
Jan 1, 2022	17.68B	702.00M	4.14%
Dec 31, 2020	16.97B	427.00M	2.58%